Iovance Biotherapeutics Poised for Strong Market Position and Financial Growth: Buy Rating Affirmed
Iovance Biotherapeutics Analyst Ratings
Piper Sandler Downgrades Iovance Biotherapeutics(IOVA.US) to Hold Rating, Cuts Target Price to $10
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
Stifel Nicolaus Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics Analyst Ratings
Iovance Biotherapeutics Analyst Ratings
JMP Securities Adjusts Price Target on Iovance Biotherapeutics to $23 From $25, Maintains Market Outperform Rating
Iovance Biotherapeutics Analyst Ratings
Iovance Biotherapeutics Analyst Ratings
Piper Sandler Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)
Analysts Conflicted on These Healthcare Names: Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals Inc (AMLX) and Vaxcyte (PCVX)
Iovance Biotherapeutics Analyst Ratings
Piper Sandler Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)
Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Merus (MRUS) and Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics (IOVA) Gets a Buy From Barclays
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Iovance Biotherapeutics (IOVA) and Intellia Therapeutics (NTLA)
Truist Adjusts Iovance Biotherapeutics' Price Target to $25 From $26, Keeps Buy Rating
Iovance Biotherapeutics Analyst Ratings